Kiley Juergens Wealth Management LLC boosted its stake in shares of Pfizer Inc. (NYSE: PFE – Get Rating) by 11.4% during the 1st quarter, Holdings Channel.com reports. The firm owned 22,093 shares of the biopharmaceutical company’s stock after buying an additional 2,257 shares during the quarter. Kiley Juergens Wealth Management LLC’s holdings in Pfizer were worth $ 1,144,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Bank OZK raised its position in Pfizer by 0.3% during the fourth quarter. Bank OZK now owns 68,883 shares of the biopharmaceutical company’s stock valued at $ 4,067,000 after purchasing an additional 195 shares during the period. TimeScale Financial Inc. raised its holdings in Pfizer by 2.9% during the 4th quarter. TimeScale Financial Inc. now owns 6,978 shares of the biopharmaceutical company’s stock valued at $ 412,000 after buying an additional 196 shares during the period. Bath Savings Trust Co raised its holdings in Pfizer by 0.5% during the 4th quarter. Bath Savings Trust Co. now owns 39,684 shares of the biopharmaceutical company’s stock valued at $ 2,344,000 after buying an additional 200 shares during the period. Fruth Investment Management raised its holdings in Pfizer by 0.7% during the 4th quarter. Fruth Investment Management now owns 29,313 shares of the biopharmaceutical company’s stock valued at $ 1,730,000 after buying an additional 200 shares during the period. Finally, Winfield Associates Inc. raised its holdings in Pfizer by 0.9% during the 4th quarter. Winfield Associates Inc. now owns 21,557 shares of the biopharmaceutical company’s stock valued at $ 1,273,000 after buying an additional 200 shares during the period. Institutional investors own 66.50% of the company’s stock.
PFE has been the topic of several recent research reports. Barclays set a $ 52.00 price target on Pfizer in a report on Tuesday, May 17th. Berenberg Bank set a $ 50.00 price target on Pfizer in a report on Friday, May 27th. JPMorgan Chase & Co. set a $ 57.00 price target on Pfizer in a report on Tuesday, May 3rd. Morgan Stanley started coverage on Pfizer in a report on Wednesday, April 6th. They set an “equal weight” rating and a $ 55.00 price target on the stock. Finally, SVB Leerink started coverage on Pfizer in a research note on Monday, May 23rd. They issued a “market perform” rating and a $ 55.00 target price on the stock. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $ 57.26.
PFE opened at $ 49.07 on Thursday. Pfizer Inc. has a 12-month low of $ 38.82 and a 12-month high of $ 61.71. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43. The business’s fifty day simple moving average is $ 50.57 and its 200-day simple moving average is $ 52.22. The company has a market capitalization of $ 275.33 billion, a price-to-earnings ratio of 11.25, a PEG ratio of 0.56 and a beta of 0.76.
Pfizer (NYSE: PFE – Get Rating) last posted its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $ 1.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $ 1.66 by ($ 0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The firm had revenue of $ 25.66 billion for the quarter, compared to the consensus estimate of $ 24.73 billion. During the same period in the previous year, the company posted $ 0.93 EPS. Pfizer’s quarterly revenue was up 76.8% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post 6.61 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 10th. Investors of record on Friday, May 13th were given a dividend of $ 0.40 per share. This represents a $ 1.60 dividend on an annualized basis and a yield of 3.26%. The ex-dividend date of this dividend was Thursday, May 12th. Pfizer’s payout ratio is currently 36.70%.
In other Pfizer news, SVP Jennifer B. Damico sold 4,000 shares of the firm’s stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $ 50.50, for a total value of $ 202,000.00. Following the completion of the sale, the senior vice president now owns 15,064 shares of the company’s stock, valued at $ 760,732. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Jennifer B. Damico sold 4,218 shares of the firm’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $ 53.96, for a total value of $ 227,603.28. Following the completion of the transaction, the senior vice president now owns 10,846 shares of the company’s stock, valued at $ 585,250.16. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 41,126 shares of company stock worth $ 2,075,003. 0.05% of the stock is owned by corporate insiders.
About Pfizer (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE: PFE – Get Rating).
Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.